Literature DB >> 26679569

Corticosteroids and the retina: a role for the mineralocorticoid receptor.

Francine Behar-Cohen1, Min Zhao.   

Abstract

PURPOSE OF REVIEW: Long-lasting devices releasing steroids have been approved recently for macular edema of various origins. Identification of the retina as a novel mineralo-sensitive tissue also raises new therapeutic options. RECENT
FINDINGS: Recently, the over activation of the mineralocorticoid receptor (MR) pathway has been shown to cause fluid accumulation in the retina, choroidal vasodilation, and to promote retinal neovascularization in hypoxic conditions. These findings indicate that MR antagonists could have beneficial effects in the treatment of retinal diseases. Central serous chorioretinopathy is a retinal disease associated with choroidal vasodilation and subretinal fluid that affects mostly men with type A personality and occurrence has been associated with steroid intake. In several independent studies, MR antagonists have shown beneficial effects, significantly reducing subretinal fluid in eyes of chronic central serous chorioretinopathy patients.
SUMMARY: The role of MR in retinal disorder is emerging and the potential association with psychological traits is considered. The place of MR antagonists for retinal diseases treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26679569     DOI: 10.1097/WCO.0000000000000284

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  9 in total

1.  The Application of Methylprednisolone Nanoscale Zirconium-Porphyrin Metal-Organic Framework (MPS-NPMOF) in the Treatment of Photoreceptor Degeneration.

Authors:  Yajie Wang; Wei Liu; Bo Yuan; Xuebo Yin; Yiming Li; Zongjin Li; Jianlin Cui; Xiaoyong Yuan; Yuhao Li
Journal:  Int J Nanomedicine       Date:  2019-12-10

2.  Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study.

Authors:  Hamid-Reza Moein; Lauren W Bierman; Eduardo A Novais; Carlos Moreira-Neto; Caroline R Baumal; Adam Rogers; Jay S Duker; André J Witkin
Journal:  Int J Retina Vitreous       Date:  2019-09-09

3.  Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy.

Authors:  Omer Farooq; Asad Habib; Masood Alam Shah; Najia Ahmed
Journal:  Pak J Med Sci       Date:  2019 Nov-Dec       Impact factor: 1.088

4.  Changes in the Foveal Outer Nuclear Layer of Central Serous Chorioretinopathy Patients Over the Disease Course and Their Response to Photodynamic Therapy.

Authors:  Kaixin Deng; Yufei Gui; Yi Cai; Zhiqiao Liang; Xuan Shi; Yaoyao Sun; Mingwei Zhao
Journal:  Front Med (Lausanne)       Date:  2022-01-14

5.  Case Report: Vogt-Koyanagi-Harada Syndrome Mimicking Acute Angle-Closure Glaucoma in a Patient Infected With Human Immunodeficiency Virus.

Authors:  Xue Bai; Rui Hua
Journal:  Front Med (Lausanne)       Date:  2022-01-12

6.  Unilateral recurrent central serous chorioretinopathy (CSCR) following COVID-19 vaccination- A multimodal imaging study.

Authors:  Srinivasan Sanjay; Isha Acharya; Ankush Kawali; Rohit Shetty; Padmamalini Mahendradas
Journal:  Am J Ophthalmol Case Rep       Date:  2022-07-06

7.  Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment.

Authors:  Jin Young Kim; Ju Byung Chae; Jisoo Kim; Dong Yoon Kim
Journal:  J Ophthalmol       Date:  2018-07-22       Impact factor: 1.909

Review 8.  Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature.

Authors:  Irini Chatziralli; Aikaterini Vlachodimitropoulou; Chrysoula Daoula; Christina Vrettou; Eleni Galani; George Theodossiadis; Panagiotis Theodossiadis
Journal:  Int J Retina Vitreous       Date:  2018-09-19

9.  Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy.

Authors:  Katrin Fasler; Jeanne M Gunzinger; Daniel Barthelmes; Sandrine A Zweifel
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.